Wyeth And Progenics Announce Preliminary Clinical Trial Results For RELISTOR Oral And Intravenous...

medicalnewstoday.com     May 23, 2008            

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR(TM) (methylnaltrexone bromide). [read full story]                    


*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies